Human TNF_alpha 10 ug
- Known as:
- Human TNF_alpha 10 ug
- Catalog number:
- 1050-10
- Product Quantity:
- 10 ug
- Category:
- -
- Supplier:
- Biovis
- Gene target:
- Human TNF_alpha 10
Related products to: Human TNF_alpha 10 ug
Related articles to: Human TNF_alpha 10 ug
- Non-alcoholic fatty liver disease (NAFLD) is an escalating global health threat that has been linked to environmental pollutants such as the highly toxic dioxin-like congener 3,3',4,4',5-pentachlorobiphenyl (PCB 126). Although PCB 126 is known to impair hepatic function, the precise mechanisms-particularly the contribution of ferroptosis, an iron-dependent, lipid-peroxidation-mediated form of cell death-remain elusive. Here, we tested the hypothesis that ferroptosis underlies PCB 126-induced NAFLD and delineated the key molecular pathways involved. Balb/c mice were intraperitoneally injected with PCB 126 (1, 5, or 10 μM/kg) for 14 days. Hepatic injury was assessed through serum biomarkers (ALT, AST, ALP), histopathology (H&E and Oil Red O staining), and mitochondrial ultrastructure via transmission electron microscopy. Ferroptosis markers (GPX4, 4-HNE, Tf receptor), lipid peroxidation (MDA, GSH, SOD), iron homeostasis, and inflammatory cytokines (IL-1β, IL-6, TNF-α) were evaluated using qPCR, Western blotting, and ELISA. Results demonstrated that PCB 126 exposure induced NAFLD, evidenced by elevated liver-to-body weight ratios, serum liver enzymes, and steatosis. Ferroptosis was implicated through reduced mitochondrial cristae, suppressed GPX4 and SLC7A11 expression, increased lipid peroxidation, and iron accumulation. Additionally, PCB 126 activated the NF-κB pathway, elevating pro-inflammatory cytokines and myeloperoxidase (MPO) activity, while oxidative stress was marked by NRF2/KEAP1/HO-1 axis disruption. In conclusion, PCB 126 promotes NAFLD in mice by triggering ferroptosis, inflammation, and oxidative stress. These findings highlight ferroptosis as a pivotal mechanistic link in PCB 126-induced NAFLD, suggesting potential therapeutic targets for mitigating pollutant-driven liver injury. - Source: PubMed
Publication date: 2025/09/16
Wang JingjingChen YichunWu HanpengYe YingrongLi YifeiZhou Ershun - The Coronavirus disease-2019 (COVID-19) pandemic continues, and the death toll continues to surge. This systematic review and meta-analysis aimed to determine the efficacy of nanocurcumin on mortality in patients with COVID-19. A systematic search was performed in PubMed, Embase, Cochrane Library, and clinicaltrials.gov up to November 2024, without language restrictions. Inclusion criteria: (1) inclusion of hospitalized patients with COVID-19 who are 18 years or older; (2) polymerase chain reaction positive for severe acute respiratory syndrome coronavirus-2; and (3) use of a randomized controlled design to make a comparison of nanocurcumin with placebo. The Cochrane risk-of-bias tool for randomized trials was used to assess the risk of bias. Studies were pooled to risk ratios (RRs) and standardized mean differences (SMDs), with 95% confidence intervals (CIs). Six trials (enrolling 333 participants) met the inclusion criteria. Nanocurcumin therapy showed significant improvements on mortality (RR 0.47, 95% CI 0.25-0.88; = 0.02), interleukin-6 (IL-6) (SMD -0.30, 95% CI -0.56 to -0.04; = 0.02), tumor necrosis factor-α (TNF-α) (SMD -0.63, 95% CI -1.16 to -0.10; = 0.02), and IL-1β (SMD -0.88, 95% CI -1.37 to -0.39; = 0.0004). Nanocurcumin significantly reduced mortality, IL-6, TNF-α, and IL-1β in hospitalized patients with COVID-19. Given the lack of safety data and concerns about the risk of bias, the use of nanocurcumin in COVID-19 requires further research. - Source: PubMed
Publication date: 2025/09/16
Shang WenliWang GuizuoHan Dong - Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition with limited response to standard anti-inflammatory therapies. Biologics targeting specific inflammatory pathways have emerged as potential treatments, but their efficacy remains variable across distinct COPD endotypes. - Source: PubMed
Publication date: 2025/09/10
Matera Maria GabriellaCalzetta LuiginoRogliani PaolaCazzola Mario - Acute ischemic stroke (AIS) often leads to hemiplegia, significantly impairing neurological function, motor ability, and daily life activities. Early precision exercise rehabilitation has emerged as a promising intervention to enhance recovery. This study evaluated its effectiveness in improving neurological function, gait performance, and self-care ability and reducing inflammatory response in hemiplegic patients. - Source: PubMed
Li HongxiaLai Yunqi - This study aimed to evaluate the effects of recurrent laryngeal nerve anatomical exposure during thyroidectomy on serum TNF-a, CRP interleukins IL-6, IL-10, and IL-1b, treatment outcomes, complications, and patient prognosis, with a specific focus on inflammatory and stress markers, including interleukins. - Source: PubMed
Luo YongtaoCheng Hui